Zacks Investment ResearchTue, 17 Mar 2026 22:11:10 GMTGossamer Bio (GOSS) Reports Q4 Loss, Beats Revenue EstimatesGOSS-4.86%
Zacks Investment ResearchThu, 05 Mar 2026 16:01:14 GMTEarnings Preview: Gossamer Bio (GOSS) Q4 Earnings Expected to DeclineGOSS-4.86%
Zacks Investment ResearchThu, 26 Feb 2026 15:56:50 GMTHere's Why Gossamer Bio (GOSS) Is a Great 'Buy the Bottom' Stock NowGOSS-4.86%
Zacks Investment ResearchThu, 26 Feb 2026 15:35:40 GMTGossamer Bio (GOSS) Loses 85% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerGOSS-4.86%
Seeking AlphaMon, 23 Feb 2026 21:25:10 GMTGossamer Bio, Inc. (GOSS) Discusses Topline Results of PROSERA Phase 3 Study in Pulmonary Arterial Hypertension TranscriptGOSS-4.86%
BenzingaMon, 23 Feb 2026 14:57:59 GMTGossamer Bio Plans FDA Talks After Narrow Miss In Key Pivotal Study, Stock SinksGOSS-4.86%
